cytochrome P450 family 4 subfamily Z member 2, pseudogeneGenealiases: []
Q-omics provides the consensus-scored CYP4Z2P profile across patient tissues and cancer cell-line models. CYP4Z2P expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, CYP4Z2P is differentially expressed in 12, with the highest sampling consensus in LUSC. Additionally, CYP4Z2P RNA expression shows 17,425 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BLCA, LUSC, and LSCC as cancer lineages where CYP4Z2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP4Z2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP4Z2P survival associations across molecular data types. CYP4Z2P RNA expression shows survival associations in the most cancer types (19), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP4Z2P RNA expression–survival associations across cancer types. High CYP4Z2P expression shows unfavorable associations in UCEC, KIRP and UCS, but favorable associations in BLCA, CESC and LUAD. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for CYP4Z2P RNA expression.
This table summarizes CYP4Z2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for CYP4Z2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP4Z2P shows lower tumor expression in LUSC, LUAD, HNSC, KICH and KIRP and higher tumor expression in BRCA. The LUSC box plot shows higher CYP4Z2P RNA expression in normal versus tumor tissue (log2 FC = −1.491, t-test p < 0.001).
This table shows molecular features associated with CYP4Z2P in patient tissues and cancer cell lines. In patient samples, CYP4Z2P shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CYP4Z2P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC.
